aimovig
novartis new zealand ltd - erenumab 140 mg/ml; - solution for injection - 140 mg/ml - active: erenumab 140 mg/ml excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - aimovig is indicated for prophylaxis of migraine in adults.
aimovig
novartis new zealand ltd - erenumab 140 mg/ml; - solution for injection - 140 mg/ml - active: erenumab 140 mg/ml excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - aimovig is indicated for prophylaxis of migraine in adults.
aimovig solution for injection 140 mg/1 ml
شركة مستودع الأدوية الأردني - the jordan drugstore co - erenumab 140 mg/1 ml - 140 mg/1 ml
dullarma 140 mg/1 cap
شركة أدوية الحكمة - hikma pharmaceuticals - ibrutinib 140 mg/1 cap - 140 mg/1 cap
elpida 140 milligram/1 tablet
شركة أدوية الحكمة - hikma pharmaceuticals - dasatinib 140 milligram/1 tablet - 140 milligram/1 tablet
merogram powder for solution for injection or infusion 1000mg 1140 milligram/1 vial
مستودع ادوية الرحمة - al rahma drug store - meropenem trihydrate 1140 milligram/1 vial - 1140 milligram/1 vial
meropenem kabi 1140 milligram/1 vial
مستودع أدوية الغروب - sun set drug store - meropenem trihydrate 1140 milligram/1 vial - 1140 milligram/1 vial
zed 140.480 milligram
مستودع أدوية النور - noor drug store - sildenafil citrate 140.480 milligram - 140.480 milligram
dasatinib dar al-dawa 140 mg/1 tab
شركة دار الدواء للتنمية والأستثمار - dar al dawa development and investment co ltd - dasatinib 140 mg/1 tab - 140 mg/1 tab
naproxen tablet, delayed release
remedyrepack inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen delayed-release tablets are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions (5.7, 5.8) ]. - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions ( 5.1) ]. risk summary use of nsaids, including naproxen delayed-release tablets, duri